- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02886234
Health Improvement Project - Providence (HIP)
Mindfulness Training to Improve ART Adherence and Reduce Risk Behavior Among Persons Living With HIV
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Two-thirds of people living with HIV show sub-optimal adherence to antiretroviral therapy (ART) and one-third engages in risky sex. Both non-adherence and risky sex have been associated with emotional distress and impulsivity. In this trial, the investigators will examine the utility of phone-delivered mindfulness training (MT) for people living with HIV. The primary outcomes comprise feasibility and acceptability of phone-delivery; secondary outcomes are estimates of efficacy of MT on adherence to ART and safer sexual practices as well as on their hypothesized antecedents.
Fifty participants will be enrolled in this parallel-group randomized clinical trial (RCT). Outpatients recruited from an HIV treatment clinic will be randomized (1:1 ratio) to either MT or to health coaching intervention; both interventions will be administered during 8 weekly phone calls. ART adherence (self-reported measure and unannounced phone pill counts), sexual behavior (self-reports and biomarkers), mindfulness, depression, stress, and impulsivity will be measured at baseline, post-intervention, and 3 months post-intervention.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02906
- The Miriam Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- HIV infection
- Sub-optimal adherence to ART (Less than "always" taking ART medication and/or viral load > 20 copies/mL);
- Psychological distress (PHQ-4 score ≥ 2);
- Recent risky sexual behavior (any unprotected sex OR > 1 sexual partner over the past 6 months)
- Access to a telephone or cell phone
Exclusion Criteria:
- Unwilling or unable to provide informed consent
- Cognitive impairment
- Non-English speaking
- Low literacy (i.e., reporting they "often" or "always" need someone to read instructions, pamphlets, or other written material from a doctor or pharmacy to them
- Enrolled in another behavioral trials
- Prior formal mindfulness training or have practiced of mindfulness or related mind-body techniques in the previous year
- Severe hearing impairment not allowing phone delivery
- Suicidal ideation
- Planning to move out of the area within the study period
- Clinic provider advising against recruitment in the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Mindfulness training (MT)
Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
|
Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks.
).
In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
|
|
Comparador Ativo: Health Coaching (HC)
Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
|
The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition.
To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Feasibility of Intervention
Prazo: post-intervention, 9 to 10 weeks after baseline
|
Feasibility - as indicated by the number of patients attending at least 50% of sessions
|
post-intervention, 9 to 10 weeks after baseline
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Acceptability of the Intervention
Prazo: post-intervention, 9 to 10 weeks after baseline
|
Number of patients reporting "very satisfied" or "mostly satisfied" with their intervention
|
post-intervention, 9 to 10 weeks after baseline
|
|
Antiretroviral Medication Adherence
Prazo: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Self-reported number of missed days of medication
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
|
Self-reported Sexual Risk Behavior
Prazo: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Self-reported risky sexual behavior as indicated by the percentage of episodes of condom protected sexual intercourse Higher values are better outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
|
Five Facet Mindfulness Questionnaire
Prazo: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Five Facet of Mindfulness Questionnaire (15 items; short form) Construct = Mindfulness Minimum total scale score = 15 Maximum total scale score = 75 Scoring: sum across all 15 items Higher scores represent a better outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
|
Perceived Stress Scale
Prazo: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Perceived Stress Scale (4-item version) Construct = perceived stress Minimum total scale score = 0 Maximum total scale score = 16 Scoring: reverse score items 2 and 3, then sum across all 4 items Higher scores represent a worse outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
|
Barratt Impulsiveness Scale
Prazo: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Barratt Impulsiveness Scale (short form, 8 items) Construct = Impulsivity Minimum total scale score = 8 Maximum total scale score = 32 Scoring: reverse score items 1, 4, 5, 6, and then sum across all 8 items Higher scores represent a worse outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
|
Patient Health Questionnaire
Prazo: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Patient Health Questionnaire (9 item version) Construct measured = depression Minimum total scale score = 0 Maximum total scale score = 27 Scoring: sum across all 9 items Higher scores represent a worse outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: MIchael P Carey, PhD, Centers for Behavioral and Preventive Medicine, The Miriam Hospital
- Investigador principal: Elena Salmoirago-Blotcher, MD, PhD, Centers for Behavioral and Preventive Medicine, The Miriam Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- R34AT008930 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .